OXYGENTA PHARMACEUTICAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.49 INR | -0.15% |
|
-6.97% | +7.48% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 77.53 | 106.1 | 74.47 | 74.47 | 341.5 | 519.8 |
| Enterprise Value (EV) 1 | 268.9 | 329.3 | 342.5 | 548.9 | 861.3 | 1,199 |
| P/E ratio | -1.71 x | -3.26 x | -1.29 x | 2.54 x | -50.1 x | -4.49 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.6 x | 0.52 x | 0.54 x | 0.14 x | 0.56 x | 1.68 x |
| EV / Revenue | 2.09 x | 1.61 x | 2.5 x | 1.05 x | 1.42 x | 3.87 x |
| EV / EBITDA | -6.73 x | -16.1 x | -4.35 x | 14 x | 58.4 x | -16.9 x |
| EV / FCF | 52.5 x | -3.88 x | -7.36 x | -4.12 x | -15.4 x | -10.1 x |
| FCF Yield | 1.9% | -25.7% | -13.6% | -24.3% | -6.5% | -9.9% |
| Price to Book | -0.24 x | -0.3 x | -0.18 x | -0.2 x | -0.99 x | -1.13 x |
| Nbr of stocks (in thousands) | 10,201 | 10,201 | 10,201 | 10,201 | 14,201 | 14,201 |
| Reference price 2 | 7.600 | 10.40 | 7.300 | 7.300 | 24.05 | 36.60 |
| Announcement Date | 10/21/18 | 9/10/19 | 12/8/20 | 12/10/21 | 9/5/22 | 9/7/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 128.7 | 205.1 | 137.2 | 521 | 605.2 | 310 |
| EBITDA 1 | -39.97 | -20.42 | -78.67 | 39.11 | 14.76 | -71.04 |
| EBIT 1 | -49.37 | -30.61 | -88.66 | 27.15 | -1.153 | -91.56 |
| Operating Margin | -38.37% | -14.93% | -64.64% | 5.21% | -0.19% | -29.53% |
| Earnings before Tax (EBT) 1 | -44.8 | -34.93 | -59.41 | 31.44 | -4.894 | -113.7 |
| Net income 1 | -45.28 | -32.54 | -57.88 | 29.3 | -6.105 | -115.7 |
| Net margin | -35.18% | -15.87% | -42.2% | 5.62% | -1.01% | -37.33% |
| EPS 2 | -4.440 | -3.190 | -5.670 | 2.870 | -0.4800 | -8.150 |
| Free Cash Flow 1 | 5.119 | -84.76 | -46.51 | -133.1 | -55.99 | -118.7 |
| FCF margin | 3.98% | -41.33% | -33.91% | -25.55% | -9.25% | -38.28% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/21/18 | 9/10/19 | 12/8/20 | 12/10/21 | 9/5/22 | 9/7/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 191 | 223 | 268 | 474 | 520 | 679 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -4.788 x | -10.93 x | -3.406 x | 12.13 x | 35.21 x | -9.556 x |
| Free Cash Flow 1 | 5.12 | -84.8 | -46.5 | -133 | -56 | -119 |
| ROE (net income / shareholders' equity) | 15.3% | 9.7% | 15.2% | -7.42% | 1.68% | 28.6% |
| ROA (Net income/ Total Assets) | -17.1% | -10% | -27.9% | 6.47% | -0.22% | -13.4% |
| Assets 1 | 264.4 | 324.2 | 207.8 | 453.1 | 2,755 | 863.8 |
| Book Value Per Share 2 | -31.30 | -34.50 | -40.10 | -37.30 | -24.40 | -32.50 |
| Cash Flow per Share 2 | 0.0100 | 0.0200 | 0.1200 | 0.4400 | 0.0500 | 0.0100 |
| Capex 1 | 4.11 | 5.69 | 5.2 | 67.4 | 49.5 | 96.4 |
| Capex / Sales | 3.19% | 2.77% | 3.79% | 12.94% | 8.17% | 31.11% |
| Announcement Date | 10/21/18 | 9/10/19 | 12/8/20 | 12/10/21 | 9/5/22 | 9/7/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +7.48% | 14.26M | |
| +55.32% | 815B | |
| +44.05% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.57% | 242B | |
| +13.31% | 218B | |
| +8.48% | 168B | |
| -2.81% | 159B |
- Stock Market
- Equities
- SSORGS Stock
- Financials Oxygenta Pharmaceutical Limited
